{"id":"antidepressant-aripiprazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Restlessness"}]},"_chembl":{"chemblId":"CHEMBL2219425","moleculeType":"Small molecule","molecularWeight":"660.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The antidepressant component (specific agent not specified) increases monoamine availability in the central nervous system, typically through reuptake inhibition. Aripiprazole, an atypical antipsychotic with partial dopamine D2 agonist activity, is used as an augmentation strategy to enhance antidepressant response and may address residual symptoms in treatment-resistant depression. This combination leverages both serotonergic and dopaminergic pathways.","oneSentence":"This combination enhances serotonergic and noradrenergic neurotransmission via antidepressant action while aripiprazole provides dopaminergic stabilization and augmentation of antidepressant efficacy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:57.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder, treatment-resistant or inadequate response to antidepressant monotherapy"}]},"trialDetails":[{"nctId":"NCT07047651","phase":"PHASE4","title":"Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.","status":"RECRUITING","sponsor":"Dr. Stavroula Rakitzi","startDate":"2025-06-04","conditions":"Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder","enrollment":40},{"nctId":"NCT05814640","phase":"PHASE1, PHASE2","title":"Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-02-20","conditions":"Depression, Sequestra","enrollment":520},{"nctId":"NCT06937476","phase":"NA","title":"Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole","status":"RECRUITING","sponsor":"Central South University","startDate":"2025-05-08","conditions":"Major Depressive Disorder (MDD), Rumination","enrollment":108},{"nctId":"NCT04747314","phase":"PHASE2, PHASE3","title":"Treating Negative Affect in Low Back Pain Patients","status":"COMPLETED","sponsor":"Ajay Wasan, MD, Msc","startDate":"2021-03-31","conditions":"Chronic Low Back Pain, Negative Affectivity","enrollment":308},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT01246765","phase":"","title":"National Pregnancy Registry for Psychiatric Medications","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2008-11","conditions":"Pregnant Women, Psychotropic Drugs","enrollment":5000},{"nctId":"NCT06049953","phase":"","title":"Maternal And Infant Antipsychotic Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-09-29","conditions":"Antipsychotics, Pregnancy","enrollment":200},{"nctId":"NCT07153406","phase":"PHASE3","title":"Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients","status":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2025-09-15","conditions":"Depressive Disorder","enrollment":220},{"nctId":"NCT06591091","phase":"PHASE2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-09","conditions":"Depression","enrollment":80},{"nctId":"NCT07024303","phase":"EARLY_PHASE1","title":"Measurement of Treatment Effects","status":"NOT_YET_RECRUITING","sponsor":"Matthew J O'Brien, PhD, BCBA-D","startDate":"2025-06-15","conditions":"Challenging Behavior, Autism Spectrum Disorder","enrollment":20},{"nctId":"NCT02752542","phase":"PHASE4","title":"Personalized Indications for CBT and Antidepressants in Treating Depression","status":"RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2016-10-31","conditions":"Major Depressive Disorder, Persistent Depressive Disorder","enrollment":80},{"nctId":"NCT05531591","phase":"PHASE4","title":"RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2019-08-01","conditions":"Depression, Dementia, Mild Cognitive Impairment","enrollment":87},{"nctId":"NCT02960763","phase":"PHASE4","title":"Optimizing Outcomes of Treatment-Resistant Depression in Older Adults","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-02-24","conditions":"Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression","enrollment":742},{"nctId":"NCT06054321","phase":"NA","title":"Psychopharmacotherapy for Depressive Patients","status":"RECRUITING","sponsor":"Chonnam National University Hospital","startDate":"2022-08-03","conditions":"Major Depressive Disorder","enrollment":400},{"nctId":"NCT05554627","phase":"PHASE4","title":"VA Aripiprazole vs Esketamine for Treatment Resistant Depression","status":"WITHDRAWN","sponsor":"VA Office of Research and Development","startDate":"2023-10-27","conditions":"Depressive Disorder, Major","enrollment":""},{"nctId":"NCT02357849","phase":"PHASE4","title":"Fluoxetine vs Aripiprazole Comparative Trial (FACT)","status":"TERMINATED","sponsor":"Northwell Health","startDate":"2014-07","conditions":"Attenuated Psychosis Syndrome","enrollment":9},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":"Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy","enrollment":180},{"nctId":"NCT02977299","phase":"PHASE4","title":"Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-05-01","conditions":"Treatment Resistant Major Depressive Disorder","enrollment":278},{"nctId":"NCT04234776","phase":"PHASE4","title":"Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2018-04-03","conditions":"Depressive Disorder","enrollment":88},{"nctId":"NCT01421342","phase":"PHASE3","title":"VA Augmentation and Switching Treatments for Improving Depression Outcomes","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2012-12","conditions":"Major Depressive Disorder","enrollment":1522},{"nctId":"NCT00953745","phase":"NA","title":"Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":43},{"nctId":"NCT00683852","phase":"PHASE3","title":"A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-09","conditions":"Major Depressive Disorder","enrollment":225},{"nctId":"NCT00220636","phase":"PHASE4","title":"Abilify as an Adjunctive Treatment for Refractory Depression","status":"COMPLETED","sponsor":"St. Luke's-Roosevelt Hospital Center","startDate":"2005-03","conditions":"Depressive Disorder, Major","enrollment":15},{"nctId":"NCT01386086","phase":"PHASE3","title":"Aripiprazole and Resistant Postpartum Depression","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2011-06","conditions":"Postpartum Depression","enrollment":10},{"nctId":"NCT00892047","phase":"PHASE4","title":"Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2009-08","conditions":"Depression","enrollment":468},{"nctId":"NCT00926835","phase":"PHASE4","title":"Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients","status":"TERMINATED","sponsor":"Ministry of Health & Welfare, Korea","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":692},{"nctId":"NCT01305707","phase":"PHASE4","title":"Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression","status":"TERMINATED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2009-07","conditions":"Depression","enrollment":104},{"nctId":"NCT00489866","phase":"PHASE2","title":"Aripiprazole Augmentation of Antidepressants in PTSD","status":"COMPLETED","sponsor":"Durham VA Medical Center","startDate":"2007-03","conditions":"PTSD","enrollment":14},{"nctId":"NCT01724372","phase":"NA","title":"The Role of Antidepressants or Antipsychotics in Preventing Psychosis","status":"WITHDRAWN","sponsor":"St. Luke's-Roosevelt Hospital Center","startDate":"2012-10","conditions":"Psychotic Disorder","enrollment":""},{"nctId":"NCT01429831","phase":"PHASE4","title":"Aripiprazole for the Augmentation of Antidepressant Therapy","status":"COMPLETED","sponsor":"Taiwan Otsuka Pharm. Co., Ltd","startDate":"2011-09","conditions":"Major Depressive Disorder","enrollment":300},{"nctId":"NCT00095758","phase":"PHASE3","title":"A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-09","conditions":"Major Depressive Disorder","enrollment":1200},{"nctId":"NCT00095823","phase":"PHASE3","title":"A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-06","conditions":"Major Depressive Disorder","enrollment":1200},{"nctId":"NCT01284218","phase":"","title":"Retrospective Database Study of Real World Abilify Outcomes in Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-01","conditions":"Depressive Disorder, Major","enrollment":23514},{"nctId":"NCT00095745","phase":"PHASE3","title":"A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-09","conditions":"Major Depressive Disorder","enrollment":1002},{"nctId":"NCT00608543","phase":"PHASE4","title":"Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2005-10","conditions":"Major Depressive Disorder","enrollment":17},{"nctId":"NCT01710163","phase":"PHASE4","title":"Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2012-06","conditions":"Bipolar I Disorder","enrollment":50},{"nctId":"NCT00556140","phase":"PHASE3","title":"The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2003-06","conditions":"Psychotic Depression","enrollment":16},{"nctId":"NCT01488266","phase":"NA","title":"Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder","status":"UNKNOWN","sponsor":"Korea University","startDate":"2011-11","conditions":"Major Depressive Disorder","enrollment":90},{"nctId":"NCT00704860","phase":"PHASE4","title":"Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism","status":"COMPLETED","sponsor":"University of Ottawa","startDate":"2005-02","conditions":"Major Depression","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Abilify"],"phase":"phase_3","status":"active","brandName":"Antidepressant + Aripiprazole","genericName":"Antidepressant + Aripiprazole","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aripiprazole is a partial agonist of the dopamine D2 receptor, classified as a small molecule. It is used in combination with an antidepressant to treat conditions such as Major Depressive Disorder, Depressive Disorder, Psychotic Disorder, Bipolar I Disorder, and Depression.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2002-11-15T00:00:00.000Z","mah":"OTSUKA","brand_name_local":"ABILIFY","application_number":"NDA021436"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2004-12-10T00:00:00.000Z","mah":"OTSUKA","brand_name_local":"ABILIFY","application_number":"NDA021713"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2006-06-07T00:00:00.000Z","mah":"OTSUKA","brand_name_local":"ABILIFY","application_number":"NDA021729"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2006-09-20T00:00:00.000Z","mah":"OTSUKA","brand_name_local":"ABILIFY","application_number":"NDA021866"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}